Hypersensitivity syndrome to antiepileptic drugs: a review including new anticonvulsants.

Anticonvulsant hypersensitivity syndrome, a potentially fatal but rare reaction, manifests as rash, fever, tender lymphadenopathy, hepatitis, and eosinophilia. To manage hypersensitivity syndrome successfully, one must recognize the symptoms early, stop the offending drug immediately, and substitute a safe, alternative anticonvulsant medication. Hypersensitivity syndrome has not been described in patients taking benzodiazepines or the newer anticonvulsants gabapentin or topiramate, and these appear to be safe substitutes for drugs that cause the reaction.

[1]  H. Hamer,et al.  Successful treatment with gabapentin in the presence of hypersensitivity syndrome to phenytoin and carbamazepine: a report of three cases , 1999, Seizure.

[2]  J. Sackellares,et al.  Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures , 1997, Neurology.

[3]  G. Bergey,et al.  Gabapentin monotherapy: I. An 8-day, double-blind, dose controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures , 1997, Neurology.

[4]  R. Stern,et al.  Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study , 1997, Neurology.

[5]  N. Levell,et al.  Systemic corticosteroids in the phenytoin hypersensitivity syndrome , 1996, The British journal of dermatology.

[6]  W. Grabski,et al.  Dilantin hypersensitivity reaction. , 1996, Cutis.

[7]  R. Stern,et al.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. , 1996, The New England journal of medicine.

[8]  J. Muglia,et al.  Anticonvulsant hypersensitivity syndrome. , 1995, Archives of internal medicine.

[9]  C. Brander,et al.  Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. , 1995, Journal of immunology.

[10]  A. D. De Vriese,et al.  Carbamazepine Hypersensitivity Syndrome: Report of 4 Cases and Review of the Literature , 1995, Medicine.

[11]  S. Brown,et al.  Rechallenge with lamotrigine after initial rash , 1995, Seizure.

[12]  R. Stern,et al.  Severe adverse cutaneous reactions to drugs. , 1994, The New England journal of medicine.

[13]  J. Pellock.  The clinical efficacy of lamotrigine as an antiepileptic drug , 1994, Neurology.

[14]  J. Fischer,et al.  Gabapentin: A New Agent for the Management of Epilepsy , 1994, The Annals of pharmacotherapy.

[15]  R. Ramsay.  Clinical efficacy and safety of gabapentin , 1994, Neurology.

[16]  M. J. Hayes,et al.  Carbamazepine‐induced pneumonitis , 1994, The Medical journal of Australia.

[17]  R. Bertz,et al.  Diazepam by Continuous Intravenous Infusion for Status Epilepticus in Anticonvulsant Hypersensitivity Syndrome , 1993, The Annals of pharmacotherapy.

[18]  R. Beran.  Cross‐Reactive Skin Eruption with Both Carbamazepine and Oxcarbazepine , 1993, Epilepsia.

[19]  V. Wahn,et al.  Severe Adverse Reaction to Carbamazepine: Significance of Humoral and Cellular Reactions to the Drug , 1992, Neuropediatrics.

[20]  M. Brodie.  Lamotrigine , 2021, Reactions Weekly.

[21]  M. Rieder,et al.  Drug‐induced hypothyroidism: The thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides , 1992, Clinical pharmacology and therapeutics.

[22]  S. Spielberg,et al.  Familial occurrence of hypersensitivity to phenytoin. , 1991, The American journal of medicine.

[23]  M. Dunn,et al.  Phenytoin Hypersensitivity Syndrome: A Case Report , 1991, DICP : the annals of pharmacotherapy.

[24]  F. Flowers,et al.  Toxic epidermal necrolysis: a review. , 1991, Journal of the American Academy of Dermatology.

[25]  B. Rzany,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. , 1991, Archives of dermatology.

[26]  C. Meijer,et al.  Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. , 1991, Journal of the American Academy of Dermatology.

[27]  M. Primohamed.  Carbamazepine-hypersensitivity : assessment of clinical and in vitro chemical cross reactivity with phenytoin and oxcarbazepine , 1991 .

[28]  J. D. Miller,et al.  Suppression of carbamazepine-induced rash with prednisone. , 1991, Neurology.

[29]  H. Askmark,et al.  Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system , 1990, Acta neurologica Scandinavica.

[30]  M. Boggild,et al.  Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure , 1989, Neurology.

[31]  W. Luginbuhl,et al.  Phenytoin-Carbamazepine Cross-Sensitivity , 1989, DICP : the annals of pharmacotherapy.

[32]  S. Spielberg,et al.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. , 1988, The Journal of clinical investigation.

[33]  E. Scheffer,et al.  Drug‐induced pseudolymphomatous skin reactions , 1988, The British journal of dermatology.

[34]  J. Fairley,et al.  Cutaneous and immunologic reactions to phenytoin. , 1988, Journal of the American Academy of Dermatology.

[35]  B. Safai,et al.  Erythema multiforme and Stevens‐Johnson syndrome in patients receiving cranial irradiation and phenytoin , 1988, Neurology.

[36]  J. Engel,et al.  Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis. , 1986, The American journal of medicine.

[37]  D. Turnbull,et al.  Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[38]  M. Murphy,et al.  Cholestatic liver dysfunction after long-term phenytoin therapy. , 1984, Archives of neurology.

[39]  R. Tomsick.  The phenytoin syndrome. , 1983, Cutis.

[40]  D. Schmidt,et al.  Fatal Toxic Epidermal Necrolysis Following Reexposure to Phenytoin: A Case Report , 1983, Epilepsia.

[41]  D. Howrie,et al.  Phenytoin-Induced Lymphadenopathy , 1983, Drug intelligence & clinical pharmacy.

[42]  C. J. Rosenthal,et al.  Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation , 1982, Cancer.

[43]  S. Spechler,et al.  Cholestasis and toxic epidermal necrolysis associated with phenytoin sodium ingestion: the role of bile duct injury. , 1981, Annals of internal medicine.

[44]  H. Gleichmann.  Studies on the mechanism of drug sensitization: T-cell-dependent popliteal lymph node reaction to diphenylhydantoin. , 1981, Clinical immunology and immunopathology.

[45]  M. Pollack,et al.  Mucocutaneous eruptions due to antiepileptic drug therapy in children , 1979, Annals of neurology.

[46]  L. Mccarthy,et al.  Fatal benign phenytoin lymphadenopathy. , 1979, Archives of internal medicine.

[47]  W. Parker,et al.  Phenytoin hepatotoxicity , 1979, Neurology.

[48]  J. Stanley,et al.  Phenytoin hypersensitivity reaction. , 1978, Archives of dermatology.

[49]  A. Rane,et al.  High incidence of a concentration-dependent skin reaction in children treated with phenytoin. , 1978, British medical journal.

[50]  G. D. de Gast,et al.  Lymphocyte-stimulation tests and patch tests to carbamazepine hypersensitivity. , 1977, Clinical and experimental immunology.

[51]  W. Mitch,et al.  Reversible renal failure and myositis caused by phenytoin hypersensitivity. , 1976, JAMA.

[52]  B. Cohen,et al.  Leukopenia as an unusual component of diphenylhydantoin hypersensitivity. A case with pruritus, rash, fever, lymphadenopathy, but low leukocyte count. , 1973, Clinical pediatrics.

[53]  J. J. Anthony.  Malignant lymphoma associated with hydantoin drugs. , 1970, Archives of neurology.

[54]  J. Pezzimenti,et al.  Anicteric hepatitis induced by diphenylhydantoin. , 1970, Archives of internal medicine.

[55]  U. Harinasula,et al.  Diphenylhydantoin sodium hepatitis. , 1968, JAMA.

[56]  S. Sommers,et al.  The development of Hodgkin's disease and lymphoma during anticonvulsant therapy. , 1966, Blood.

[57]  A. Gropper.  Diphenylhydantoin sensitivity; report of fatal case with hepatitis and exfoliative dermatitis. , 1956, The New England journal of medicine.

[58]  J. Segal,et al.  Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. , 1950, The New England journal of medicine.

[59]  H. Merritt,et al.  SODIUM DIPHENYL HYDANTOINATE IN THE TREATMENT OF CONVULSIVE DISORDERS , 1938 .